{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:24:39Z","timestamp":1791545079161,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T00:00:00Z","timestamp":1575244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["251037\/F20"],"award-info":[{"award-number":["251037\/F20"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["179573"],"award-info":[{"award-number":["179573"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["287927"],"award-info":[{"award-number":["287927"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006095","name":"Ministry of Health and Care Services | Helse S\u00f8r-\u00d8st RHF","doi-asserted-by":"publisher","award":["2018052"],"award-info":[{"award-number":["2018052"]}],"id":[{"id":"10.13039\/501100006095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intravitreal injections of antibody-based biologics targeting vascular endothelial growth factor (VEGF) are highly effective and have markedly decreased the risk of visual impairment associated with prevalent retinal diseases, such as neovascular age-related macular degeneration and diabetes macular oedema. The diseases are chronic in their nature, and most patients need long-term therapy to suppress disease activity. We previously reported a compounding method for repackaging and storage of aflibercept (Eylea), a commonly used anti-VEGF biologic, in silicone oil-coated plastic syringes without compromising drug stability or activity. In addition to improving safety and time spent per patient, compounding of anti-VEGF biologics enables single-dose vials to be split into multiple syringes, thereby considerably reducing waste and drug expenses. However, symptomatic silicone oil droplets may deposit in the eye\u2019s vitreous body after repetitive injections. To fully avoid this complication, we here report on a novel pharmaceutical compounding method using silicone oil-free syringes and a 33\u2009G \u00d7 9\u2009mm Low Dead Space Needle hub injection needle. We evaluate the method for three anti-VEGF biologics commonly used in ophthalmology: aflibercept, ranibizumab (Lucentis) and bevacizumab (Avastin). Our results show that compounding and storage for one week does not compromise the functional activity of the biologics and allows for safe and cost-effective compounding of anti-VEGF biologics for intravitreal injections in prefilled silicone oil-free syringes.<\/jats:p>","DOI":"10.1038\/s41598-019-54226-7","type":"journal-article","created":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T11:37:14Z","timestamp":1575286634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes"],"prefix":"10.1038","volume":"9","author":[{"given":"Heidrun Elisabeth","family":"Lode","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torleif Tollefsrud","family":"Gj\u00f8lberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stian","family":"Foss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magne Sand","family":"Sivertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rgen","family":"Brustugun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein Kalsnes","family":"J\u00f8rstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Carstens","family":"Moe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Terje","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,2]]},"reference":[{"key":"54226_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ophtha.2015.09.018","volume":"123","author":"K Berg","year":"2016","unstructured":"Berg, K. et al. Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol Two-Year Results. Ophthalmology 123, 51\u201359 (2016).","journal-title":"Ophthalmology"},{"key":"54226_CR2","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/aos.13480","volume":"95","author":"\u00d8 J\u00f8rstad","year":"2017","unstructured":"J\u00f8rstad, \u00d8., Faber, R. & Moe, M. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. Acta Ophthalmologica 95, 460\u2013463 (2017).","journal-title":"Acta Ophthalmologica"},{"key":"54226_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/138070","volume":"2015","author":"M Ishikawa","year":"2015","unstructured":"Ishikawa, M., Jin, D., Sawada, Y., Abe, S. & Yoshitomi, T. Future Therapies of Wet Age-Related Macular Degeneration. J Ophthalmol 2015, 1\u201310 (2015).","journal-title":"J Ophthalmol"},{"key":"54226_CR4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1755-3768.2011.02179.x","volume":"90","author":"K Kinnunen","year":"2012","unstructured":"Kinnunen, K., Petrovski, G., Moe, M. C., Berta, A. & Kaarniranta, K. Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration. Acta Ophthalmol 90, 299\u2013309 (2012).","journal-title":"Acta Ophthalmol"},{"key":"54226_CR5","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"W Wong","year":"2014","unstructured":"Wong, W. et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Global Heal 2, e106\u201316 (2014).","journal-title":"Lancet Global Heal"},{"key":"54226_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-015-0010-y","volume":"1","author":"R Merani","year":"2015","unstructured":"Merani, R. & Hunyor, A. P. Endophthalmitis following intravitreal anti-vascular endothelial growth factor (VEGF) injection: a comprehensive review. International Journal of Retina and Vitreous 1, 9 (2015).","journal-title":"International Journal of Retina and Vitreous"},{"key":"54226_CR7","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/jamaophthalmol.2015.2556","volume":"133","author":"BL VanderBeek","year":"2015","unstructured":"VanderBeek, B. L., Bonaffini, S. G. & Ma, L. Association of Compounded Bevacizumab With Postinjection Endophthalmitis. JAMA Ophthalmology 133, 1159\u20131164 (2015).","journal-title":"JAMA Ophthalmology"},{"key":"54226_CR8","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier, J. S. et al. Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration. Ophthalmology 119, 2537\u201348 (2012).","journal-title":"Ophthalmology"},{"key":"54226_CR9","first-page":"1897","volume":"364","author":"C Group","year":"2011","unstructured":"Group, C. et al. Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. New Engl. J Medicine 364, 1897\u20131908 (2011).","journal-title":"J Medicine"},{"key":"54226_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20525-8","volume":"8","author":"M Sivertsen","year":"2018","unstructured":"Sivertsen, M. et al. Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties. Scientific Reports 8, 2101 (2018).","journal-title":"Scientific Reports"},{"key":"54226_CR11","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1007\/s00347-010-2299-0","volume":"107","author":"S Grisanti","year":"2010","unstructured":"Grisanti, S. & Tura, A. Qualit\u00e4tsunterschiede zwischen Ranibizumab aus Originalbeh\u00e4ltern und aus Fertigspritzen. Der Ophthalmol 107, 1123\u20131132 (2010).","journal-title":"Der Ophthalmol"},{"key":"54226_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jcjo.2016.11.012","volume":"52","author":"S Cao","year":"2017","unstructured":"Cao, S., Cui, J., Matsubara, J. & Forooghian, F. Long-term in vitro functional stability of compounded ranibizumab and aflibercept. Canadian Journal of Ophthalmology \/ Journal Canadien d\u2019Ophtalmologie 52, 273\u2013276 (2017).","journal-title":"Canadian Journal of Ophthalmology \/ Journal Canadien d\u2019Ophtalmologie"},{"key":"54226_CR13","first-page":"32","volume":"133","author":"NA Yannuzzi","year":"2015","unstructured":"Yannuzzi, N. A. et al. Evaluation of Compounded Bevacizumab Prepared for Intravitreal Injection. JAMA. Ophthalmology 133, 32\u201339 (2015).","journal-title":"Ophthalmology"},{"key":"54226_CR14","first-page":"70","volume":"19","author":"M Pereboom","year":"2015","unstructured":"Pereboom, M. et al. Stability assessment of repackaged bevacizumab for intravitreal administration. International journal of pharmaceutical compounding 19, 70\u20132 (2015).","journal-title":"International journal of pharmaceutical compounding"},{"key":"54226_CR15","first-page":"798","volume":"98","author":"N Phasukkijwatana","year":"2015","unstructured":"Phasukkijwatana, N., Tanterdtham, J. & Lertpongparkpoom, D. Stability of Bevacizumab Divided in Multiple Doses for Intravitreal Injection. Journal of the Medical Association of Thailand Chotmaihet thangphaet 98, 798\u2013803 (2015).","journal-title":"Journal of the Medical Association of Thailand Chotmaihet thangphaet"},{"key":"54226_CR16","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2174\/1389201015666140619120834","volume":"15","author":"L Signorello","year":"2014","unstructured":"Signorello, L. et al. Quantification, Microbial Contamination, Physico-chemical Stability of Repackaged Bevacizumab Stored Under Different Conditions. Curr Pharm Biotechno 15, 113\u2013119 (2014).","journal-title":"Curr Pharm Biotechno"},{"key":"54226_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.pharma.2012.03.006","volume":"70","author":"M Paul","year":"2012","unstructured":"Paul, M. et al. Long-term stability of bevacizumab repackaged in 1mL polypropylene syringes for intravitreal administration. Annales Pharmaceutiques Fran\u00e7aises 70, 139\u2013154 (2012).","journal-title":"Annales Pharmaceutiques Fran\u00e7aises"},{"key":"54226_CR18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/IAE.0b013e31820a67e4","volume":"31","author":"CA Mccannel","year":"2011","unstructured":"Mccannel, C. A. Meta-Analysis of endophthalmitis after intravitreal injection of Anti\u2013Vascular endothelial growth factor agents: Causative Organisms and Possible Prevention Strategies. Retina 31, 654 (2011).","journal-title":"Retina"},{"key":"54226_CR19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/01.iae.0000225354.92444.7a","volume":"26","author":"SJ Kri","year":"2006","unstructured":"Kri, S. J. et al. Six-Month Stability of bevacizumab (avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or Freezing. retina 26, 519 (2006).","journal-title":"retina"},{"key":"54226_CR20","unstructured":"Subhi, Y., Kjer, B. & Munch, I. Prefilled syringes for intravitreal injection reduce preparation time. Danish medical journal 63 (2016)."},{"key":"54226_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1177\/2474126417735963","volume":"1","author":"GG Emerson","year":"2017","unstructured":"Emerson, G. G. Silicone Oil Droplets are More Common in Fluid From BD Insulin Syringes as Compared to Other Syringes. J Vitreoretin Dis 1, 401\u2013406 (2017).","journal-title":"J Vitreoretin Dis"},{"key":"54226_CR22","doi-asserted-by":"publisher","unstructured":"Melo, G. et al. Release of silicone oil and the off-label use of syringes in ophthalmology. Brit J Ophthalmol bjophthalmol-2019-313823, https:\/\/doi.org\/10.1136\/bjophthalmol-2019-313823 (2019).","DOI":"10.1136\/bjophthalmol-2019-313823"},{"issue":"7","key":"54226_CR23","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1001\/jamaophthalmol.2017.1815","volume":"135","author":"Rahul N. Khurana","year":"2017","unstructured":"Khurana, R. N., Chang, L. K. & Porco, T. C. Incidence of Presumed Silicone Oil Droplets in the Vitreous Cavity After Intravitreal Bevacizumab Injection With Insulin Syringes. Jama Ophthalmol, https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.1815 (2017).","journal-title":"JAMA Ophthalmology"},{"key":"54226_CR24","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1097\/IAE.0b013e31816c6868","volume":"28","author":"SJ Bakri","year":"2008","unstructured":"Bakri, S. J. & Ekdawi, N. S. Intravitreal Silicone Oil Droplets After Intravitreal Drug Injections. Retin 28, 996 (2008).","journal-title":"Retin"},{"key":"54226_CR25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ajoc.2017.07.009","volume":"10","author":"JH Yu","year":"2018","unstructured":"Yu, J. H. et al. Silicone oil droplets following intravitreal bevacizumab injections. Am J Ophthalmol Case Reports 10, 142\u2013144 (2018).","journal-title":"Am J Ophthalmol Case Reports"},{"key":"54226_CR26","unstructured":"Avery, R. L. et al. Large Silicone Droplets After Intravitreal Bevacizumab (Avastin). Retin Cases Brief Reports, Publish Ahead of Print, 1 (2017)."},{"key":"54226_CR27","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"J Holash","year":"2002","unstructured":"Holash, J. et al. VEGF-Trap: A VEGF blocker with potent antitumor effects. Proc National Acad Sci 99, 11393\u201311398 (2002).","journal-title":"Proc National Acad Sci"},{"key":"54226_CR28","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4161\/mabs.3.5.16983","volume":"3","author":"TT Kuo","year":"2011","unstructured":"Kuo, T. T. & Aveson, V. G. Neonatal Fc receptor and IgG-based therapeutics. mAbs 3, 422\u201330 (2011).","journal-title":"mAbs"},{"key":"54226_CR29","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/nri2155","volume":"7","author":"DC Roopenian","year":"2007","unstructured":"Roopenian, D. C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol 7, 715\u2013725 (2007).","journal-title":"Nat Rev Immunol"},{"key":"54226_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.clim.2006.09.001","volume":"122","author":"J Kim","year":"2007","unstructured":"Kim, J., Hayton, W. L., Robinson, J. M. & Anderson, C. L. Kinetics of FcRn-mediated recycling of IgG and albumin in human: Pathophysiology and therapeutic implications using a simplified mechanismbased model. Clinical Immunology 122, 146\u2013155 (2007).","journal-title":"Clinical Immunology"},{"key":"54226_CR31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.immuni.2004.05.007","volume":"20","author":"M Yoshida","year":"2004","unstructured":"Yoshida, M. et al. Human Neonatal Fc Receptor Mediates Transport of IgG into Luminal Secretions for Delivery of Antigens to Mucosal Dendritic Cells. Immunity 20, 769\u2013783 (2004).","journal-title":"Immunity"},{"key":"54226_CR32","first-page":"2803","volume":"15","author":"H Kim","year":"2009","unstructured":"Kim, H., Robinson, S. B. & Csaky, K. G. FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye. Molecular vision 15, 2803\u201312 (2009).","journal-title":"Molecular vision"},{"key":"54226_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.exer.2016.11.007","volume":"154","author":"HL Deissler","year":"2017","unstructured":"Deissler, H. L., Lang, G. K. & Lang, G. E. Neonatal Fc receptor FcRn is involved in intracellular transport of the Fc fusion protein aflibercept and its transition through retinal endothelial cells. Experimental Eye Research 154, 39\u201346 (2017).","journal-title":"Experimental Eye Research"},{"key":"54226_CR34","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.exer.2015.12.013","volume":"145","author":"M Dithmer","year":"2016","unstructured":"Dithmer, M. et al. The role of Fc-receptors in the uptake and transport of therapeutic antibodies in the retinal pigment epithelium. Experimental Eye Research 145, 187\u2013205 (2016).","journal-title":"Experimental Eye Research"},{"key":"54226_CR35","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1167\/iovs.13-12574","volume":"55","author":"MB Powner","year":"2014","unstructured":"Powner, M. B., McKenzie, J. A., Christianson, G. J., Roopenian, D. C. & Fruttiger, M. Expression of neonatal Fc receptor in the eye. Investigative ophthalmology & visual science 55, 1607\u201315 (2014).","journal-title":"Investigative ophthalmology & visual science"},{"key":"54226_CR36","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1167\/iovs.07-0871","volume":"49","author":"H Kim","year":"2008","unstructured":"Kim, H. et al. Mapping of the Neonatal Fc Receptor in the Rodent Eye. Investigative Ophthalmology & Visual Science 49, 2025\u20132029 (2008).","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"54226_CR37","unstructured":"Inc., R. FDA Approves Eylea (aflibercept) Injection Prefilled Syringe, https:\/\/www.drugs.com\/newdrugs\/fda-approves-eylea-aflibercept-prefilled-syringe-5028.html (2019)."},{"key":"54226_CR38","unstructured":"Reuter, B. & Petersen, C. Syringe Siliconization. Techno Pharm 238\u2013244 (2012)."},{"issue":"7","key":"54226_CR39","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1080\/02713683.2016.1276195","volume":"42","author":"Elad Moisseiev","year":"2017","unstructured":"Moisseiev, E., Rudell, J., Tieu, E. V. & Yiu, G. Effect of Syringe Design on the Accuracy and Precision of Intravitreal Injections of Anti-VEGF Agents. Curr Eye Res 1\u20135, https:\/\/doi.org\/10.1080\/02713683.2016.1276195 (2017).","journal-title":"Current Eye Research"},{"key":"54226_CR40","doi-asserted-by":"crossref","unstructured":"Sampat, K., Wolfe, J. D., Shah, M. K. & Garg, S. J. Accuracy and Reproducibility of Seven Brands of Small-Volume Syringes Used for Intraocular Drug Delivery. Ophthalmic Surg Lasers Imaging Retin 44, 385\u2013389 (2013).","DOI":"10.3928\/23258160-20130601-02"},{"key":"54226_CR41","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1111\/j.1755-3768.2010.02072.x","volume":"90","author":"CH Meyer","year":"2012","unstructured":"Meyer, C. H., Liu, Z., Brinkmann, C., Rodrigues, E. B. & Helb, H. Accuracy, precision and repeatability in preparing the intravitreal dose with a 1.0-cc syringe. Acta Ophthalmol 90, e165\u2013e166 (2012).","journal-title":"Acta Ophthalmol"},{"key":"54226_CR42","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1111\/j.1442-9071.2010.02447.x","volume":"39","author":"VS Stefano","year":"2011","unstructured":"Stefano, V. S. et al. Experimental investigation of needles, syringes and techniques for intravitreal injections. Clin Exp Ophthalmol 39, 236\u2013242 (2011).","journal-title":"Clin Exp Ophthalmol"},{"key":"54226_CR43","unstructured":"International Organization for Standardization. ISO 14644-1 Cleanrooms and associated controlled environments - Part 1: Classification of air cleanliness by particle concentration, Available at, https:\/\/www.iso.org\/standard\/53394.html, (Accessed: 2018) (2018)."},{"key":"54226_CR44","unstructured":"European Commission. The Rules Governing Medicinal Products in the European Union; Volume 4; EU Guidelines to Good Manufacturing Practice; Medicinal Products for Human and Veterinary Use; Annex; Manufacture of Sterile Medicinal Products (corrected version). Available at, https:\/\/ec.europa.eu\/health\/documents\/eudralex\/vol-4_en, (Accessed: 2018)."},{"key":"54226_CR45","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1111\/j.1742-4658.2008.06551.x","volume":"275","author":"JT Andersen","year":"2008","unstructured":"Andersen, J. T. et al. Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues. Febs J 275, 4097\u20134110 (2008).","journal-title":"Febs J"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54226-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54226-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54226-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:44:29Z","timestamp":1671295469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-54226-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,2]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["54226"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-54226-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,2]]},"assertion":[{"value":"24 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Magne S. Sivertsen is an investigator in an Alcon sponsored clinical trial. \u00d8ystein K. J\u00f8rstad has received lecture fees from Allergan, Alcon, and Bayer, has been a member of a Bayer advisory board and an investigator in an Alcon sponsored clinical trial. Morten C. Moe is member of Bayer and Novartis advisory boards and is an investigator in an Alcon sponsored clinical trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18021"}}